neurodegenerative


Also found in: Dictionary, Medical, Wikipedia.

neurodegenerative

[‚nu̇·rō·di′jen·rəd·iv]
(pathology)
Characterized by the gradual and progressive loss of nerve cells.
References in periodicals archive ?
A major hurdle for treating neurodegenerative diseases is the inability of most biologics to cross the tightly controlled blood-brain barrier (BBB).
TSX: 4502) and South San Francisco, California-based neurodegenerative disease therapeutic-focused Denali Therapeutics (NASDAQ: DNLI) have entered into a strategic option and collaboration agreement to develop and commercialize up to three specified therapeutic product candidates for neurodegenerative diseases, the company said.
The agreement concerns the development and commercialisation of up to three specified therapeutic product candidates for neurodegenerative diseases.
The collaboration is focused on using [F-18]MK-6240 as a biomarker in Janssen neurodegenerative disease research studies.
In an effort to examine the impact of receiving metformin treatment on the incidence of neurodegenerative disease and the association between length of metformin exposure and the risk of neurodegenerative diseases, the researchers used the Veterans Affairs database from 2004 to 2010 to study 6,046 patients who were at least 50 years of age with type 2 diabetes mellitus and were receiving long-term insulin treatment.
Neurodegenerative Disease Market: Drivers & Restraints
Astrocytes are neural supporting cells shown to be involved in neurodegenerative diseases.
When, in rare occurrences, PrP becomes misshapen, it causes neurodegenerative diseases in cows (SN: 1/10/04, p.
Based on positive findings on accepted clinical assessment (plus CMC scores less than 42), 30 participants were determined to have neurodegenerative MCI, 35 had vascular MCI, and 8 had Parkinson's-Lewy body MCI.
Parkinson disease (PD) and Alzheimer disease (AD), the two most common neurodegenerative disorders in American adults, are of purely genetic origin in a minority of cases and appear in most instances to arise through interactions among genetic and environmental factors.
The original agreement between Prana Biotechnology and the University of Melbourne was signed in May 1999 with the objective of furthering Prana's research program into the underlying mechanisms of Alzheimer's disease and related neurodegenerative disorders.
Guest edited by Gregory Cuny (University of Houston, TX, USA) in September 2012, Future Medicinal Chemistry published its special focus issue on neurodegenerative disease.